Login
$KLRA
$12.68 -$0.59 (4.48%) Live

$KLRA 8-K SEC Filings

Filed On Filing
04 Nov 2026 8-K: Results of Operations and Financial Condition

Ribupatide oral global Phase 3 program expected to begin in 1H 2027 following completion of End-of-Phase 2 meeting with FDA

12 Aug 2026 8-K: Results of Operations and Financial Condition

IND for ribupatide oral active with U.S. FDA, initiation of global Phase 3 obesity trials planned for the first half of 2027

26 May 2026 8-K: Results of Operations and Financial Condition

Important progress across four clinical-stage programs demonstrating depth and breadth of obesity pipeline

20 Apr 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Other Events

The address of the registered office of Kailera Therapeutics, Inc. (the “Corporation”) in the State of Delaware, and the name of its registered agent at such address, shall be as set forth in the Corporation’s certificate of incorporatio...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support